VRTX · earnings call history
Vertex Pharmaceuticals Q1 FY26 — Strong Growth Across Portfolio and Rapid Pipeline Advancement
Read the briefVertex Pharmaceuticals Q4 FY25 — Strong Diversification and Pipeline Progress
Read the briefVertex Pharmaceuticals Q3 FY25 — Strong Revenue Growth and Pipeline Advancement
Read the briefVertex Q4 FY24 — Strong CF Growth, New Product Launches, and Pipeline Advancement
Read the briefBrowse all US companies on the earnings-call register.